发明名称 Method of weight management
摘要 Provided are methods of determining if an individual is a responder to treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof. Also provided are methods for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management. Also provided are methods for weight management in an individual in need thereof. Also provided are compounds, compositions, and kits for use in a method of weight management in an individual.
申请公布号 US9169213(B2) 申请公布日期 2015.10.27
申请号 US201414242442 申请日期 2014.04.01
申请人 Arena Pharmaceuticals, Inc. 发明人 Sanchez Matilde;Shanahan William R.
分类号 C07D223/16;A61K31/55;A61K31/137 主分类号 C07D223/16
代理机构 代理人
主权项 1. A method of weight management for an individual in need thereof comprising: treating the individual for 12 weeks with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof wherein the individual is administered a dose equivalent to 20 mg of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1 H-3-benzazepine hydrochloride per day, and continuing said treatment if the individual has achieved at least 5% weight loss by week 12, whereby achievement of at least 5% weight loss by week 12 correlates with a likelihood of the individual achieving an additional decrease in an assessment of weight after about one year, wherein the method further comprises administering a reduced-calorie diet to the individual, wherein, prior to beginning the treatment, the individual has an initial body mass index (BMI) of >27 kg/m2, and wherein the pharmaceutical composition is administered orally to the individual.
地址 San Diego CA US